Francis T Kimani, Kelvin K Thiongó, Maureen A Otinga, Lewis K Mbabu, Mary N Ombati, Stanley K Kitur, Sarah A Ochieng', Lucy N Wachira, Damaris K Matoke-Muhia, Luna Kamau
{"title":"肯尼亚中部高地的疟疾流行、传播潜力和以青蒿素为基础的联合疗法的疗效:这是一个以前被认为无疟疾的地区。","authors":"Francis T Kimani, Kelvin K Thiongó, Maureen A Otinga, Lewis K Mbabu, Mary N Ombati, Stanley K Kitur, Sarah A Ochieng', Lucy N Wachira, Damaris K Matoke-Muhia, Luna Kamau","doi":"10.1186/s12936-024-05214-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The current study sought to re-evaluate malaria prevalence, susceptibility to artemisinin-based combination therapy (ACT), transmission patterns and the presence of malaria vectors in the Kikuyu area of the Kenyan Central highlands, a non-traditional/low risk malaria transmission zone where there have been anecdotal reports of emerging malaria infections.</p><p><strong>Methods: </strong>Sampling of adult mosquitoes was done indoors, while larvae were sampled outdoors in June 2019. The malaria clinical study was an open label non-randomized clinical trial where the efficacy of one ACT drug, was evaluated in two health facilities. Microscopy was used at the facility while nested 18 s rRNA subunit gene PCR amplification and MSP-1 and MSP-2 family alleles genotyping was done in the laboratory. Anti-malarial resistance gene markers Pfk13 and Pfmdr1 were profiled.</p><p><strong>Results: </strong>Anopheles funestus mosquitoes were the predominant vectors at 76.35% of all larvae collections (N = 148). Only two non-blood fed, parasites negative adult mosquitoes were collected from houses sampled. Parasitological analysis of the 838 patients screened resulted in 41 positives whose treatment outcome was 100% Adequate Clinical and Parasitological Response (ACPR). From the 35 positive samples genotyped, 29 (82.9%) were polyclonal. The overall mean MOI was 2.8 (95% CI 2.36-3.35). The MOI for msp-1 and msp-2 genes, was 2.02 (95% CI 0.72-2.27) and 2.9 (95% CI 2.22-3.55), and parasite strains range of 1-3 and 1-7, respectively. Polyclonal variation in the two genes was at 76.4% and 70.3%, respectively. The Pfk13 gene revealed no single nucleotide polymorphisms (SNP) associated with suspected artemisinin resistance nor was there any pfmdr1 N86 mutant allele detected.</p><p><strong>Conclusion: </strong>The Plasmodium infections positivity rate observed in the study site was very low but significant. A proportion of participants who tested positive did not report recent history of travel. This observation together with the finding of competent known vectors can probably suggest that several of the cases could have been acquired and transmitted locally. The observed genetic diversity and polyclonal variations was on the contrary and suggest that these are imported cases. This however does not rule out a likely changing malaria transmission scenario in this zone, thus the need for further investigations.</p>","PeriodicalId":18317,"journal":{"name":"Malaria Journal","volume":"24 1","pages":"10"},"PeriodicalIF":2.4000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726929/pdf/","citationCount":"0","resultStr":"{\"title\":\"Malaria prevalence, transmission potential and efficacy of artemisinin-based combination therapy in the Kenyan Central highlands: a zone previously characterized as malaria-free.\",\"authors\":\"Francis T Kimani, Kelvin K Thiongó, Maureen A Otinga, Lewis K Mbabu, Mary N Ombati, Stanley K Kitur, Sarah A Ochieng', Lucy N Wachira, Damaris K Matoke-Muhia, Luna Kamau\",\"doi\":\"10.1186/s12936-024-05214-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The current study sought to re-evaluate malaria prevalence, susceptibility to artemisinin-based combination therapy (ACT), transmission patterns and the presence of malaria vectors in the Kikuyu area of the Kenyan Central highlands, a non-traditional/low risk malaria transmission zone where there have been anecdotal reports of emerging malaria infections.</p><p><strong>Methods: </strong>Sampling of adult mosquitoes was done indoors, while larvae were sampled outdoors in June 2019. The malaria clinical study was an open label non-randomized clinical trial where the efficacy of one ACT drug, was evaluated in two health facilities. Microscopy was used at the facility while nested 18 s rRNA subunit gene PCR amplification and MSP-1 and MSP-2 family alleles genotyping was done in the laboratory. Anti-malarial resistance gene markers Pfk13 and Pfmdr1 were profiled.</p><p><strong>Results: </strong>Anopheles funestus mosquitoes were the predominant vectors at 76.35% of all larvae collections (N = 148). Only two non-blood fed, parasites negative adult mosquitoes were collected from houses sampled. Parasitological analysis of the 838 patients screened resulted in 41 positives whose treatment outcome was 100% Adequate Clinical and Parasitological Response (ACPR). From the 35 positive samples genotyped, 29 (82.9%) were polyclonal. The overall mean MOI was 2.8 (95% CI 2.36-3.35). The MOI for msp-1 and msp-2 genes, was 2.02 (95% CI 0.72-2.27) and 2.9 (95% CI 2.22-3.55), and parasite strains range of 1-3 and 1-7, respectively. Polyclonal variation in the two genes was at 76.4% and 70.3%, respectively. The Pfk13 gene revealed no single nucleotide polymorphisms (SNP) associated with suspected artemisinin resistance nor was there any pfmdr1 N86 mutant allele detected.</p><p><strong>Conclusion: </strong>The Plasmodium infections positivity rate observed in the study site was very low but significant. A proportion of participants who tested positive did not report recent history of travel. This observation together with the finding of competent known vectors can probably suggest that several of the cases could have been acquired and transmitted locally. The observed genetic diversity and polyclonal variations was on the contrary and suggest that these are imported cases. This however does not rule out a likely changing malaria transmission scenario in this zone, thus the need for further investigations.</p>\",\"PeriodicalId\":18317,\"journal\":{\"name\":\"Malaria Journal\",\"volume\":\"24 1\",\"pages\":\"10\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-01-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726929/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Malaria Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12936-024-05214-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malaria Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12936-024-05214-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
研究背景本研究旨在重新评估肯尼亚中部高地基库尤地区的疟疾流行率、对青蒿素类复方疗法(ACT)的敏感性、传播模式以及疟疾病媒的存在情况:成蚊采样在室内进行,幼虫采样于 2019 年 6 月在室外进行。疟疾临床研究是一项开放标签的非随机临床试验,在两家医疗机构对一种青蒿素综合疗法药物的疗效进行评估。在医疗机构使用显微镜,在实验室进行巢式 18 s rRNA 亚基基因 PCR 扩增以及 MSP-1 和 MSP-2 家族等位基因基因分型。对抗疟基因标记 Pfk13 和 Pfmdr1 进行了分析:结果:按蚊是主要的传播媒介,占幼虫采集总数的 76.35%(N = 148)。从采样的房屋中只收集到两只不吸血、寄生虫阴性的成蚊。对筛查出的 838 名患者进行寄生虫学分析后发现,41 名阳性患者的治疗结果是 100%临床和寄生虫学反应充分(ACPR)。在 35 份基因分型阳性样本中,29 份(82.9%)为多克隆样本。总体平均 MOI 为 2.8(95% CI 2.36-3.35)。msp-1 和 msp-2 基因的 MOI 分别为 2.02(95% CI 0.72-2.27)和 2.9(95% CI 2.22-3.55),寄生虫株数范围分别为 1-3 株和 1-7 株。这两个基因的多克隆变异率分别为 76.4% 和 70.3%。Pfk13 基因没有发现与青蒿素抗药性相关的单核苷酸多态性(SNP),也没有发现 pfmdr1 N86 突变等位基因:在研究地点观察到的疟原虫感染阳性率很低,但意义重大。一部分检测呈阳性的参与者没有报告最近的旅行史。这一观察结果以及已知病媒的发现可能表明,一些病例可能是在当地感染和传播的。而观察到的基因多样性和多克隆变异则与此相反,表明这些病例是输入病例。不过,这并不能排除该地区疟疾传播情况可能发生变化的可能性,因此需要进一步调查。
Malaria prevalence, transmission potential and efficacy of artemisinin-based combination therapy in the Kenyan Central highlands: a zone previously characterized as malaria-free.
Background: The current study sought to re-evaluate malaria prevalence, susceptibility to artemisinin-based combination therapy (ACT), transmission patterns and the presence of malaria vectors in the Kikuyu area of the Kenyan Central highlands, a non-traditional/low risk malaria transmission zone where there have been anecdotal reports of emerging malaria infections.
Methods: Sampling of adult mosquitoes was done indoors, while larvae were sampled outdoors in June 2019. The malaria clinical study was an open label non-randomized clinical trial where the efficacy of one ACT drug, was evaluated in two health facilities. Microscopy was used at the facility while nested 18 s rRNA subunit gene PCR amplification and MSP-1 and MSP-2 family alleles genotyping was done in the laboratory. Anti-malarial resistance gene markers Pfk13 and Pfmdr1 were profiled.
Results: Anopheles funestus mosquitoes were the predominant vectors at 76.35% of all larvae collections (N = 148). Only two non-blood fed, parasites negative adult mosquitoes were collected from houses sampled. Parasitological analysis of the 838 patients screened resulted in 41 positives whose treatment outcome was 100% Adequate Clinical and Parasitological Response (ACPR). From the 35 positive samples genotyped, 29 (82.9%) were polyclonal. The overall mean MOI was 2.8 (95% CI 2.36-3.35). The MOI for msp-1 and msp-2 genes, was 2.02 (95% CI 0.72-2.27) and 2.9 (95% CI 2.22-3.55), and parasite strains range of 1-3 and 1-7, respectively. Polyclonal variation in the two genes was at 76.4% and 70.3%, respectively. The Pfk13 gene revealed no single nucleotide polymorphisms (SNP) associated with suspected artemisinin resistance nor was there any pfmdr1 N86 mutant allele detected.
Conclusion: The Plasmodium infections positivity rate observed in the study site was very low but significant. A proportion of participants who tested positive did not report recent history of travel. This observation together with the finding of competent known vectors can probably suggest that several of the cases could have been acquired and transmitted locally. The observed genetic diversity and polyclonal variations was on the contrary and suggest that these are imported cases. This however does not rule out a likely changing malaria transmission scenario in this zone, thus the need for further investigations.
期刊介绍:
Malaria Journal is aimed at the scientific community interested in malaria in its broadest sense. It is the only journal that publishes exclusively articles on malaria and, as such, it aims to bring together knowledge from the different specialities involved in this very broad discipline, from the bench to the bedside and to the field.